Australia markets closed
  • ALL ORDS

    7,649.30
    -32.00 (-0.42%)
     
  • ASX 200

    7,342.60
    -27.60 (-0.37%)
     
  • AUD/USD

    0.7255
    -0.0043 (-0.59%)
     
  • OIL

    73.08
    -0.22 (-0.30%)
     
  • GOLD

    1,754.10
    +4.30 (+0.25%)
     
  • BTC-AUD

    57,215.69
    -3,354.54 (-5.54%)
     
  • CMC Crypto 200

    1,025.13
    -83.79 (-7.56%)
     
  • AUD/EUR

    0.6187
    -0.0023 (-0.37%)
     
  • AUD/NZD

    1.0319
    +0.0005 (+0.05%)
     
  • NZX 50

    13,259.55
    -46.37 (-0.35%)
     
  • NASDAQ

    15,316.58
    +140.07 (+0.92%)
     
  • FTSE

    7,067.75
    -10.60 (-0.15%)
     
  • Dow Jones

    34,764.82
    +506.50 (+1.48%)
     
  • DAX

    15,536.12
    -107.85 (-0.69%)
     
  • Hang Seng

    24,192.16
    -318.82 (-1.30%)
     
  • NIKKEI 225

    30,248.81
    +609.41 (+2.06%)
     

MindMed Interim CEO on the growing competition in psychedelics industry

In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Robert Barrow, MindMed Interim CEO, joins Yahoo Finance to discuss then transition in MindMed’s CEO, future outlook for the company and the psychedelics industry.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting